Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study

医学 二线治疗 移植 外科 淋巴瘤 内科学 临床试验 一线治疗 二线疗法 肿瘤科 临床研究阶段 相(物质) 放射科 一级处理 生存分析 意向治疗分析 第二线 氟达拉滨
作者
Peter Borchmann,Tom van Meerten,Gloria Iacoboni,Pierre Bories,Peter Dreger,Pim Mutsaers,László Gopcsa,Matthias Edinger,Lajos Gergely,Bastian von Tresckow,Peter Neumeister,Normann Steiner,Ulrich Jäger,Ana Triguero Moreno,Laimonas Griškevičius,François Lemonnier,Jaap A. van Doesum,Marie José Kersten,Jakob Daniel Rudzki,Nirav N Shah
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:27 (11): 1403-1419
标识
DOI:10.1016/s1470-2045(26)00290-1
摘要

Background Anti-CD19 CAR T-cell therapy is the standard second-line treatment for patients with relapsed or refractory large B-cell lymphoma. However, there is no evidence from randomised controlled trials in patients ineligible for transplantation. To address this gap, we compared zamtocabtagene autoleucel (zamto-cel), a CAR T-cell therapy directed at CD20 and CD19, with rituximab–gemcitabine–oxaliplatin (R-GemOx) chemoimmunotherapy in patients ineligible for transplantation with relapsed or refractory large B-cell lymphoma. Methods DALY 2-EU is an open-label, multicentre, randomised, phase 2 trial conducted at 45 centres across 12 countries in Europe. Eligible patients were adults (aged ≥18 years) with second-line relapsed or refractory large B-cell lymphoma confirmed histologically who were ineligible for transplantation and had received first-line chemoimmunotherapy containing a combination of an anthracycline-based regimen and an anti-CD20 monoclonal antibody, with Eastern Cooperative Oncology Group performance status score of 2 or less. Patients were randomly assigned (1:1) to zamto-cel (single intravenous infusion of 2·5 × 10 6 fresh (ie, non-cryopreserved) CAR T-cells per kg, capped at 100 kg, produced in a closed automated system) or R-GemOx (rituximab [375 mg/m 2 intravenously on day 1], gemcitabine [1000 mg/m 2 intravenously on day 1 or 2], and oxaliplatin [100 mg/m 2 intravenously on day 1 or 2] administered for up to eight 14-day cycles). Randomisation was done with an interactive web response system and stratified by age, gender, lactate dehydrogenase, International Prognostic Index, histology, time to relapse after the start of first-line therapy, and country. The primary endpoint was event-free survival assessed by a masked independent review committee and compared all patients randomly assigned to the zamto-cel and R-GemOx groups using a one-sided log-rank test. Safety was assessed in all patients who received study treatment. This ongoing trial is registered with ClinicalTrials.gov (NCT04844866). Findings Between Oct 14, 2021, and Jul 16, 2024, 219 patients were screened and 160 were randomly assigned to zamto-cel (n=82) and R-GemOx (n=78). The median age was 74·0 years (IQR 70·5–77·0). Patients were predominantly male (100 [63%] of 160 were men and 60 [38%] women) and White (91 [57%]), with race not reported for 64 (40%). Median vein-to-vein time for zamto-cel was 15 days (IQR 15–16). With a median follow-up of 17·0 months (IQR 9·0–22·8), event-free survival was longer in the zamto-cel group than in the R-GemOx group (6·21 months [95% CI 3·84–13·77] vs 2·53 months [1·97–3·35]; HR 0·39 [95% CI 0·27–0·58]; p<0·0001). Grade 3 or higher treatment-emergent adverse events occurred in 63 (83%) of 76 with zamto-cel and in 65 (86%) of 76 with R-GemOx. The most common grade 3–4 adverse events were neutropenia (28 [37%] with zamto-cel and 17 [22%] with R-GemOx), anaemia (11 [14%] and 12 [16%]), and decreased neutrophil count (20 [26%] and seven [9%]). Serious adverse events occurred in 31 (41%) patients with zamto-cel and 50 (66%) with R-GemOx, most commonly malignant neoplasm progression (11 [14%] and 38 [50%]), cytokine release syndrome (CRS; six [8%] and none), and immune effector cell-associated neurotoxicity syndrome (four [5%] and none). Treatment-related deaths occurred in two (3%) of 82 patients with zamto-cel (due to CRS and haemophagocytic lymphohistiocytosis) and in one (1%) of 78 with R-GemOx (malignant lymphoma progression). Interpretation The risk–benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation. Funding Miltenyi Biomedicine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被文静梦竹采纳,获得10
刚刚
酷酷的小钟完成签到,获得积分10
刚刚
NexusExplorer的应助被傅三毒采纳,获得10
刚刚
cdcq完成签到,获得积分10
刚刚
mimi完成签到 ,获得积分10
1秒前
du完成签到,获得积分10
1秒前
LL完成签到,获得积分10
1秒前
水煮电吹风的应助被111采纳,获得10
1秒前
美好的老黑完成签到 ,获得积分10
1秒前
wenbo完成签到,获得积分10
2秒前
260929667完成签到,获得积分10
2秒前
1234发布了新的文献求助10
2秒前
2秒前
大力荷花发布了新的文献求助10
2秒前
vvvvv完成签到,获得积分10
2秒前
愉快数据线完成签到,获得积分10
3秒前
3秒前
顶刊相见发布了新的文献求助30
3秒前
顾矜的应助被ldz采纳,获得10
3秒前
炫迈口香糖完成签到,获得积分10
3秒前
小亦雪发布了新的文献求助10
3秒前
元谷雪的应助被阔达沂采纳,获得10
3秒前
pgxr完成签到 ,获得积分10
3秒前
冷艳诗双完成签到 ,获得积分10
3秒前
无忧sxt发布了新的文献求助10
4秒前
温暖雅山完成签到,获得积分10
4秒前
lily完成签到,获得积分10
4秒前
腼腆的立辉完成签到,获得积分10
4秒前
wave8013发布了新的文献求助10
5秒前
畅快羊青完成签到 ,获得积分10
5秒前
5秒前
6秒前
Wuuuu完成签到,获得积分10
6秒前
6秒前
6秒前
Owen的应助被大王叫我来巡山采纳,获得10
6秒前
一秒的剧情完成签到,获得积分10
6秒前
supman完成签到,获得积分10
6秒前
zizi完成签到 ,获得积分10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105